Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial.

Butler J, Khan MS, Anker SD, Fonarow GC, Kim RJ, Nodari S, O'Connor CM, Pieske B, Pieske-Kraigher E, Sabbah HN, Senni M, Voors AA and 4 more

Show all authors

Udelson JE, Carr J, Gheorghiade M, Filippatos G

Journal of cardiac failure14 Feb 2020Cited by 81 (Europe PMC)

PMID32068002DOI10.1016/j.cardfail.2020.02.001PepBankPUB-32068002

Publisher page PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with heart failure with reduced ejection fraction, neither elamipretide dose changed left ventricular ejection fraction significantly compared with placebo.
In plain wordsIn adults with heart failure, neither dose of elamipretide changed the heart's ejection fraction more than placebo.
Peptide
Elamipretide (SS-31)
Outcome
No significant changeChange in LVEF
Study
n = 71
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
4 mg and 40 mg · subcutaneous · 28 consecutive daysAs given in this study (human).
Source sentences
Summary
Also, no significant differences in change in LVESV and LVEF were observed between placebo and either of the elamipretide groups.
1 context sentence(design, population, supporting numbers)
Summary · context
We randomized 71 patients with HFrEF (LVEF ≤ 40%) in a double-blind, placebo-controlled trial in a 1:1:1 ratio to receive placebo, 4 mg or 40 mg elamipretide once daily for 28 consecutive days.
Report a problemFND-3206800203
02HumanRandomized controlled trialSafety outcome
In adults with heart failure with reduced ejection fraction, rates of study drug-related adverse events were similar in the placebo and both elamipretide groups.
In plain wordsIn adults with heart failure, drug-related side effects were about equally common with elamipretide and with placebo.
Peptide
Elamipretide (SS-31)
Outcome
No significant changeStudy drug-related adverse events
Study
n = 71
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
4 mg and 40 mg · subcutaneous · 28 consecutive daysAs given in this study (human).
Source sentences
Summary
Rates of any study drug-related adverse events were similar in the 3 groups.
1 context sentence(design, population, supporting numbers)
Summary · context
We randomized 71 patients with HFrEF (LVEF ≤ 40%) in a double-blind, placebo-controlled trial in a 1:1:1 ratio to receive placebo, 4 mg or 40 mg elamipretide once daily for 28 consecutive days.
Report a problemFND-3206800204
03HumanRandomized controlled trialEfficacy outcome
In adults with heart failure with reduced ejection fraction, elamipretide 4 mg once daily did not change left ventricular end systolic volume significantly compared with placebo at week 4.
In plain wordsIn adults with heart failure, 4 mg of elamipretide daily did not reduce the left ventricle's end systolic volume more than placebo.
Peptide
Elamipretide (SS-31)
Outcome
No significant changeChange in LVESV from baseline to week 4, 4 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
4 mg · subcutaneous · 28 consecutive daysAs given in this study (human).
Measurements
LVESV difference of means vs placebo
−0.3 mL
4 mg
Source sentences
Summary
The change in LVESV from baseline to week 4 was not significantly different between elamipretide 4 mg (89.4 mL to 85 mL; difference, -4.4 mL) or 40 mg (77.9 mL to 76.6 mL; difference, -1.2 mL) compared with placebo
2 context sentences(design, population, supporting numbers)
Summary · context
4 mg vs placebo: difference of means, -0.3; 95% CI, -4.6 to 4.0; P = 0.90
Summary · context
We randomized 71 patients with HFrEF (LVEF ≤ 40%) in a double-blind, placebo-controlled trial in a 1:1:1 ratio to receive placebo, 4 mg or 40 mg elamipretide once daily for 28 consecutive days.
Report a problemFND-3206800201
04HumanRandomized controlled trialEfficacy outcome
In adults with heart failure with reduced ejection fraction, elamipretide 40 mg once daily did not change left ventricular end systolic volume significantly compared with placebo at week 4.
In plain wordsIn adults with heart failure, 40 mg of elamipretide daily did not reduce the left ventricle's end systolic volume more than placebo.
Peptide
Elamipretide (SS-31)
Outcome
No significant changeChange in LVESV from baseline to week 4, 40 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
40 mg · subcutaneous · 28 consecutive daysAs given in this study (human).
Measurements
LVESV difference of means vs placebo
2.3 mL
40 mg
Source sentences
Summary
The change in LVESV from baseline to week 4 was not significantly different between elamipretide 4 mg (89.4 mL to 85 mL; difference, -4.4 mL) or 40 mg (77.9 mL to 76.6 mL; difference, -1.2 mL) compared with placebo
2 context sentences(design, population, supporting numbers)
Summary · context
40 mg vs placebo: difference of means, 2.3; 95% CI, -1.9 to 6.5; P  =  0.28
Summary · context
We randomized 71 patients with HFrEF (LVEF ≤ 40%) in a double-blind, placebo-controlled trial in a 1:1:1 ratio to receive placebo, 4 mg or 40 mg elamipretide once daily for 28 consecutive days.
Report a problemFND-3206800202

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.